RPE

Recycled Plastic Packaging Answers the Call of Eco-conscious Consumers, Leading the Charge toward a Greener Tomorrow with a Forecasted US$ 61.2 billion Market Valuation by 2034 | Future Market Insights, Inc.

Retrieved on: 
Monday, January 8, 2024
Plastic, Government, Recycling, Research, Polyethylene, RPE, Ecolab, Waste management, PCR, Climate change, Growth, Carbon, TotalEnergies, Competitive landscape, FMI, Environment

The Recycled Plastic Packaging Market is poised for significant growth, with its size expected to increase from US$ 28.9 billion in 2024 to US$ 61.2 billion by 2034.

Key Points: 
  • The Recycled Plastic Packaging Market is poised for significant growth, with its size expected to increase from US$ 28.9 billion in 2024 to US$ 61.2 billion by 2034.
  • Over the next decade, a promising 7.8% CAGR in the demand for recycled plastic packaging is projected to drive this expansion.
  • The benefits that recycled plastic packaging materials provide to the environment are a strong factor propelling the market expansion.
  • Government rules are influencing packaging, encouraging innovation, and propelling the growth of the recycled plastic packaging market.

Recycled Plastic Packaging Answers the Call of Eco-conscious Consumers, Leading the Charge toward a Greener Tomorrow with a Forecasted US$ 61.2 billion Market Valuation by 2034 | Future Market Insights, Inc.

Retrieved on: 
Monday, January 8, 2024
Plastic, Government, Recycling, Research, Polyethylene, RPE, Ecolab, Waste management, PCR, Climate change, Growth, Carbon, TotalEnergies, Competitive landscape, FMI, Environment

The Recycled Plastic Packaging Market is poised for significant growth, with its size expected to increase from US$ 28.9 billion in 2024 to US$ 61.2 billion by 2034.

Key Points: 
  • The Recycled Plastic Packaging Market is poised for significant growth, with its size expected to increase from US$ 28.9 billion in 2024 to US$ 61.2 billion by 2034.
  • Over the next decade, a promising 7.8% CAGR in the demand for recycled plastic packaging is projected to drive this expansion.
  • The benefits that recycled plastic packaging materials provide to the environment are a strong factor propelling the market expansion.
  • Government rules are influencing packaging, encouraging innovation, and propelling the growth of the recycled plastic packaging market.

Cognition Therapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024
Biology, Work, Geographic atrophy, SHIMMER, Alzheimer's disease, Dementia, Neuron, ACTC, Iris (anatomy), EEG, Lewy body, RPE, Antibody, Letter, AMD, Brain, Therapy, Clinical trial, ADAS, SPARC, Society, DLB, SHINE, Cognition, Vance DeGeneres, Biomarker, Toxicity, Optimism, Manuscript, Cell, Patient, Magnification, Synapse, Diagnosis, Safety, Pharmaceutical industry

PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024. The full text of the letter follows:

Key Points: 
  • PURCHASE, N.Y., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), today announced that CEO Lisa Ricciardi has issued a Letter to Shareholders to provide an update on recent pipeline developments and a preview of the company’s strategy in 2024.
  • The full text of the letter follows:
    The year ahead holds great promise for Cognition Therapeutics.
  • As we work towards these important milestones, we take stock of the achievements that give rise to optimism at Cognition Therapeutics and in the broader medical community.
  • For Cognition, expanding the pipeline for CT1812 to dry AMD has the potential to grow Cognition’s value across multiple age-related diseases.

RxCell Announces $4,600,000 Investment from DMR Global Venture and Regenosis, Plans for Second Raise of $15,000,000 for IND Testing in Q4 2023

Retrieved on: 
Tuesday, December 5, 2023
Infectious Diseases, Finance, Clinical Trials, Professional Services, Stem Cells, Biotechnology, Health, Pharmaceutical, General Health, RPE, SERI, National University of Singapore, Notifiable disease, IND, Patient, USD, Investigational New Drug, Cell death, NUS, AMD, RPC, Retinal pigment epithelium, Cell, Name, National university, Pharmaceutical industry, Medical device

RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis.

Key Points: 
  • RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis.
  • Furthermore, RxCell is gearing up for a substantial second capital raise of $15,000,000 in Q4 2023.
  • The global Age-related Macular Degeneration (AMD) Market, an integral segment RxCell operates in, had a valuation of USD 7.47 billion in 2021.
  • Professor Xianmin Zeng, CEO of RxCell, remarked, "We're thrilled to align with DMR Global Venture and Regenosis.

MISI Changes Name to Technology Advancement Center to Reflect Evolving Mission and Value Offered to the Community

Retrieved on: 
Tuesday, November 14, 2023
Technology, Professional Services, Small Business, Science, Security, Other Science, Research, Other Defense, Training, Software, Networks, Education, Other Professional Services, Defense, Mobile, Wireless, Hardware, Data Management, RPE, STEM, Organization, Workforce, United States Armed Forces, Head, Rail transport, Small business, Ecosystem, Mindscape (company), Military, Communication, K-12, Government, MISI, Renewable energy, Tourism

MISI is pleased to re-introduce itself with a new name: Technology Advancement Center ( TAC ).

Key Points: 
  • MISI is pleased to re-introduce itself with a new name: Technology Advancement Center ( TAC ).
  • Over the last 12 months, it became clear that the covenants under which MISI was founded have expanded immensely.
  • Our nation requires an outpost for government and industry to come together and develop cutting edge technology.
  • TAC leadership is dedicated to evolving and meeting the challenge of protecting and defending our interests at home and abroad head-on.

Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Stem Cells, Biotechnology, Pharmaceutical, Optical, Oncology, Health, Health Technology, Clinical Trials, Webcast, RPE, Interest, B2M, Research, VAC, D, Therapy, Visual acuity, OCT, IND, Lineage Cell Therapeutics, Eterna, INL, Patient, FDA, Collaboration, G&A, OPL, Expense, Investigational New Drug, NYSE American, Trial of the century, ELM, AMD, Geographic atrophy, Roche, Survival, Partnership, Congress, Letter, TASE, NK, Pharmaceutical industry, Fine chemical, Vaccine, Genentech

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the third quarter ended September 30, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “The Lineage team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs, supporting our alliances and working to establish new collaborations,” stated Brian M. Culley, Lineage CEO.
  • Interested parties may access today’s conference call and webcast, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
  • A live webcast of the conference call will be available online in the Investors section of Lineage’s website.

Amcor and NOVA Chemicals announce agreement to source mechanically recycled polyethylene

Retrieved on: 
Wednesday, November 8, 2023
ASX, RPE, Recycling, Environment, MOU, AMC, Nova Chemicals, Plastic, Nova, NYSE, AMCR, Bottled water, Lumber, Amcor

DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films. Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.

Key Points: 
  • DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films.
  • Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.
  • The supply agreement would enable Amcor to purchase SYNDIGO™ rPE resin, manufactured at NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, which is projected to be in operation as early as 2025.
  • The recycling facility was announced in July as a significant expansion of NOVA Chemicals' Circular Solutions business.

Amcor and NOVA Chemicals announce agreement to source mechanically recycled polyethylene

Retrieved on: 
Wednesday, November 8, 2023
ASX, RPE, Recycling, Environment, MOU, AMC, Nova Chemicals, Plastic, Nova, NYSE, AMCR, Bottled water, Lumber, Amcor

DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films. Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.

Key Points: 
  • DEERFIELD, Ill., Nov. 8, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX:AMC), a global leader in developing and producing responsible packaging solutions, today announced a Memorandum of Understanding (MOU) with leading sustainable polyethylene producer NOVA Chemicals Corporation ("NOVA Chemicals") for the purchase of mechanically recycled polyethylene resin (rPE) for use in flexible packaging films.
  • Increasing the use of rPE in flexible packaging applications is an important element of Amcor's commitment to support packaging circularity.
  • The supply agreement would enable Amcor to purchase SYNDIGO™ rPE resin, manufactured at NOVA Chemicals' first mechanical recycling facility in Connersville, Indiana, which is projected to be in operation as early as 2025.
  • The recycling facility was announced in July as a significant expansion of NOVA Chemicals' Circular Solutions business.

Endogena Therapeutics Secures FDA Green Light for Breakthrough AMD Treatment

Retrieved on: 
Tuesday, October 24, 2023
Vance DeGeneres, FDA, IND, Food, Hope, AMD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Doctor of Philosophy, MBA, Geographic atrophy, Cell, Retinitis pigmentosa, Iris (anatomy), EA, RPE, GA, Regenerative medicine, Therapy, Patient, SAN, Investigational New Drug, Pharmaceutical industry, Management

The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) has granted clearance for Endogena's Investigational New Drug (IND) application, opening the door to a groundbreaking clinical investigation of EA 2351.
  • This innovative compound offers hope to patients battling geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD).
  • Endogena Therapeutics remains dedicated to its mission of unlocking the body's regenerative potential and making a meaningful impact on patients' lives.
  • This latest achievement reinforces the company's commitment to advancing innovative therapies for conditions that urgently require novel treatment options.

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting

Retrieved on: 
Tuesday, October 24, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, Janus, Medical Affairs Bureau, Lineage Cell Therapeutics, AMD, AAO, Cell, Geographic atrophy, OD, RPE, Division, San Francisco Marriott Marquis, American Academy, GA, American Academy of Ophthalmology, Lineage, Annual general meeting, Macular degeneration, Roche, TASE, CFA, NYSE American, San Francisco, Therapy, Patient, Food and Drug Administration, Pharmaceutical industry, Ophthalmology, Genentech

In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .

Key Points: 
  • In addition, the results of imaging analyses demonstrating evidence of rapid improvement in outer retinal structure and continued clinical benefit in subjects from a Phase 1/2a clinical study of RG6501 ( OpRegen ) (ClinicalTrials.gov Identifier: NCT02286089 ), have been accepted for presentation at Eyecelerator 2023 .
  • Eyecelerator will occur prior to the American Academy of Ophthalmology (AAO) 2023 Annual Meeting and will be held at the San Francisco Marriott Marquis on Thursday, November 2nd, 2023.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.